Immunovant (IMVT) EPS (Weighted Average and Diluted) (2020 - 2026)
Immunovant (IMVT) reported EPS (Weighted Average and Diluted) of -$0.73 for Q1 2026, down 15.87% on a YoY basis from -$0.87 in Q1 2025, and down 19.67% quarter-over-quarter from -$0.61 in Q4 2025.
Immunovant (IMVT) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Immunovant has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.73 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 15.87% year-over-year to -$0.73; the trailing twelve-month figure through Mar 2026 stood at -$2.78 (down 1.83% YoY), and the FY2026 full-year result was -$2.77, down 1.47% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.73, down from -$0.61 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.35 in Q2 2022, with the low at -$0.76 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.56 across 5 years, with a median of -$0.57 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) rose 26.53% — and 2024, when it plunged 111.11%.
- Immunovant's EPS (Weighted Average and Diluted) stood at -$0.49 in 2022, then increased by 26.53% to -$0.36 in 2023, then sank by 111.11% to -$0.76 in 2024, then advanced by 19.74% to -$0.61 in 2025, then retreated by 19.67% to -$0.73 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.73 (Q1 2026), -$0.61 (Q4 2025), and -$0.73 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -0.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.73 |
| Dec 31, 2025 | -0.61 |
| Sep 30, 2025 | -0.73 |
| Jun 30, 2025 | -0.71 |
| Mar 31, 2025 | -0.63 |
| Dec 31, 2024 | -0.76 |
| Sep 30, 2024 | -0.74 |
| Jun 30, 2024 | -0.60 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -0.36 |
| Sep 30, 2023 | -0.45 |
| Jun 30, 2023 | -0.57 |
| Mar 31, 2023 | -0.45 |
| Dec 31, 2022 | -0.49 |
| Sep 30, 2022 | -0.41 |
| Jun 30, 2022 | -0.35 |
| Mar 31, 2022 | -0.41 |
| Dec 31, 2021 | -0.36 |
| Sep 30, 2021 | -0.35 |
| Jun 30, 2021 | -0.31 |